Effectiveness,Durability,and Safety of Dolutegravir and Lamivudine Versus Dolutegravir,Lamivudine,and Abacavir in a Real-Life Cohort of HIV-Infected Adults

Abstract

Background:

Dolutegravir (DTG) plus lamivudine (2-DR) is suggested as an initial and switch option in HIV-1 treatment.

Objective:

To analyze the effectiveness, durability, and safety of 2-DR compared with DTG plus abacavir/lamivudine (3-DR).

Methods:

This was an observational, ambispective study that included all treatment-naïve (TN) and treatment-experienced (TE) patients who started 2-DR or 3-DR between July 1, 2018, and November 30, 2020. The primary end point was noninferiority, at 24 and 48 weeks, of 2-DR versus 3-DR regarding the percentage of patients with viral load (VL)≥50 and 200 copies/mL in TN (4% margin) and VL<50 and 200 copies/mL in TE (margin 12%). Durability of response, and safety were also measured.

Results:

242 patients were included (53 TN and 189 TE). Two TN patients on 2-DR had VL≥50 copies/mL and 1 had VL≥200 copies/mL at week 24. In TE patients on 2-DR, 90.2% achieved VL<200 copies/mL at week 24 (difference: 3.8%; 95% CI = −6.3% to 14%) and 91.8% at week 48 (difference: 0.06%; 95% CI = −9% to 10%), meeting noninferiority criteria. Among the 53 TN patients, only 1 VF was observed in 2-DR. In TN patients, the risk of treatment discontinuation was similar between groups (hazard ratio [HR] = 0.37; P = 0.15); similar rates were also found in TE patients (HR = 0.94; P = 0.85). TE patients on 2-DR showed a better safety profile compared with 3-DR patients (P<0.001).

Conclusion and Relevance:

Our results did not show noninferiority in terms of virological effectiveness. Nevertheless, all effectiveness measures support the use of 2-DR in a real-life cohort of TN and TE. Additionally, durability and safety of 2-DR were confirmed to be similar to that of 3-DR.

Keywords

HIV infection lamivudine dolutegravir effectiveness safety and dual therapy naïve patients antiretroviral therapy

Get full access to this article

View all access options for this article.

References

Smit

Brinkman

Geerlings

, et al; ATHENA observational cohort. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015;15:810-818. doi:10.1016/S1473-3099(15)00056-0

Kelly

Nyaku

Taiwo

. Two-drug treatment approaches in HIV: finally getting somewhere? Drugs. 2016;76:523-531. doi:10.1007/s40265-016-0553-8

Dorjee

Choden

Baxi

Steinmaus

Reingold

. Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: a systematic review and meta-analyses of results from 17 epidemiologic studies. Int J Antimicrob Agents. 2018;52:541-553. doi:10.1016/j.ijantimicag.2018.07.010

Eyawo

Brockman

Goldsmith

, et al. Risk of myocardial infarction among people living with HIV: an updated systematic review and meta-analysis. BMJ Open. 2019;9:e025874. doi:10.1136/bmjopen-2018-025874

Vella

Schwartländer

Sow

Eholie

Murphy

. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. AIDS. 2012;26:1231-1241. doi:10.1097/QAD.0b013e32835521a3

de Miguel Buckley

Montejano

Stella-Ascariz

Arribas

. New strategies of ARV: the road to simplification. Curr HIV/AIDS Rep. 2018;15:11-19. doi:10.1007/s11904-018-0371-6

World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. 2nd ed. World Health Organization; 2016.

García

Lozano

. Gesida Consensus Document/National AIDS Plan regarding antiretroviral treatment in adults infected with human immunodeficiency virus (update January 2019) [in Spanish]. Accessed July 9, 2021. https://gesida-seimc.org/wp-content/uploads/2019/01/gesida_DC_TAR_2019_v_final.pdf

European AIDS Clinical Society. Guidelines: version 9.1. Accessed July 9, 2021. https://www.eacsociety.org/files/2018_guidelines-9.1-english.pdf

10.

Van Wyk

Ajana

Bisshop

, et al. Efficacy and safety of switching to dolutegravir/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO Study. Clin Infect Dis. 2020;71:1920-1929. doi:10.1093/cid/ciz1243

11.

Cahn

Madero

Arribas

, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393:143-155. doi:10.1016/S0140-6736(18)32462-0

12.

European AIDS Clinical Society. Guidelines: version 10.1. Accessed July 9, 2021. https://www.eacsociety.org/files/guidelines-10.1_30032021_1.pdf

13.

Orkin

Oka

Philibert

, et al. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. Lancet HIV. 2021;8:e185-e196. doi:10.1016/S2352-3018(20)30340-4

14.

Swindells

Andrade-Villanueva

Richmond

, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382:1112-1123. doi:10.1056/NEJMoa1904398

15.

Cadiñanos

Montejano

de Miguel Buckley

Marcelo

Arribas

. Risks and benefits of reducing the number of drugs to treat HIV-1 infection. Expert Opin Drug Saf. 2021;20:397-409. doi:10.1080/14740338.2021.1887135

16.

Hidalgo-Tenorio

Cortés

Gutiérrez

, et al. DOLAMA study: effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients. Medicine (Baltimore). 2019;98:e16813. doi:10.1097/MD.0000000000016813

17.

Cahn

Rolón

Figueroa

Gun

Patterson

Sued

. Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study. J Int AIDS Soc. 2017;20:21678. doi:10.7448/IAS.20.01.21678

18.

Taiwo

Zheng

Stefanescu

, et al. ACTG A5353: a pilot study of dolutegravir plus lamivudine for initial treatment of human immunodeficiency virus-1 (HIV-1)-infected participants with HIV-1 RNA <500 000 copies/mL. Clin Infect Dis. 2018;66:1689-1697. doi:10.1093/cid/cix1083

19.

Joly

Burdet

Landman

, et al. Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL). J Antimicrob Chemother. 2019;74:739-745. doi:10.1093/jac/dky467

20.

Lombardi

Belmonti

Borghetti

Ciccullo

Fabbiani

Di Giambenedetto

. Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy. Infez Med. 2020;28:461-463.

21.

Cahn

Madero

Arribas

, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020;83:310-318. doi:10.1097/QAI.0000000000002275

22.

Borghetti

Baldin

Lombardi

, et al. Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV-1 replication. HIV Med. 2018;19:452-454. doi:10.1111/hiv.12611.

23.

Lepik

Harrigan

Yip

, et al. Emergent drug resistance with integrase strand transfer inhibitor-based regimens. AIDS. 2017;31(10):1425-1434. doi:10.1097/QAD.0000000000001494

24.

Cahn

Madero

Arribas

, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment–naive adults with HIV-1 infection—3-year results from the GEMINI Studies. Abstract presented at: HIV Drug Therapy Glasgow 2020; October 5-8, 2020; virtual meeting.

25.

Kennedy-Martin

Curtis

Faries

Robinson

Johnston

. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials. 2015;16:495. doi:10.1186/s13063-015-1023-4.

26.

Ciccullo

Baldin

Dusina

, et al. Efficacy and safety of dolutegravir plus lamivudine as a first-line regimen in clinical practice. AIDS Res Hum Retroviruses. 2021;37:486-488. doi:10.1089/AID.2020.0276

27.

Lombardi

Belmonti

Borghetti

, et al. Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study. J Antimicrob Chemother. 2020;75:1599-1603. doi:10.1093/jac/dkaa058